{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:31:43Z","timestamp":1781623903334,"version":"3.54.5"},"reference-count":72,"publisher":"The Japanese Society for Medical Mycology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.3314\/mmj.24.004","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T22:15:12Z","timestamp":1725056112000},"page":"49-57","source":"Crossref","is-referenced-by-count":4,"title":["Antimicrobial Tolerance in Cross-Kingdom Dual-Species Biofilms Formed by Fungi and Bacteria"],"prefix":"10.3314","volume":"65","author":[{"given":"Sanae","family":"Kurakado","sequence":"first","affiliation":[{"name":"Department of Microbiology, Meiji Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Meiji Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Eshima","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Meiji Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Meiji Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Donlan RM, Costerton JW: Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167–93, 2002.","DOI":"10.1128\/CMR.15.2.167-193.2002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Davies D: Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2: 114–22, 2003.","DOI":"10.1038\/nrd1008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al: Guidelines for treatment of candidiasis. Clin Infect Dis 38: 161–89, 2004.","DOI":"10.1086\/380796"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al: Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54: 1110–22, 2012.","DOI":"10.1093\/cid\/cis021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309–17, 2004.","DOI":"10.1086\/421946"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Bartoletti M, Rinaldi M, Pasquini Z, Scudeller L, Piano S, Giacobbe DR, et al: Risk factors for candidemia in hospitalized patients with liver cirrhosis: a multicenter case-control-control study. Clin Microbiol Infect 27: 276–82, 2021.","DOI":"10.1016\/j.cmi.2020.04.030"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ohki S, Shime N, Kosaka T, Fujita N: Impact of host- and early treatment-related factors on mortality in ICU patients with candidemia: a bicentric retrospective observational study. J Intensive Care 8: 30, 2020.","DOI":"10.1186\/s40560-020-00450-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Poissy J, Damonti L, Bignon A, Khanna N, Von Kietzell M, Boggian K, et al: Risk factors for candidemia: a prospective matched case-control study. Crit Care 24: 109, 2020.","DOI":"10.1186\/s13054-020-2766-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Vit\u00e1lis E, Nagy F, T\u00f3th Z, Forg\u00e1cs L, Boz\u00f3 A, Kardos G, et al: Candida<\/i> biofilm production is associated with higher mortality in patients with candidaemia. Mycoses 63: 352–60, 2020.","DOI":"10.1111\/myc.13049"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al: Epidemiology and outcomes of candidemia in 2019 patients: Data from the Prospective Antifungal Therapy Alliance registry. Clin Infect Dis 48: 1695–703, 2009.","DOI":"10.1086\/599039"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Brunetti G, Navazio AS, Giuliani A, Giordano A, Proli EM, Antonelli G, et al: Candida<\/i> blood stream infections observed between 2011 and 2016 in a large Italian university hospital: a time-based retrospective analysis on epidemiology, biofilm production, antifungal agents consumption and drug-susceptibility. PLoS One 14: e0224678, 2019.","DOI":"10.1371\/journal.pone.0224678"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Rajendran R, Sherry L, Nile CJ, Sherriff A, Johnson EM, Hanson MF, et al: Biofilm formation is a risk factor for mortality in patients with Candida albicans<\/i> bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect 22: 87–93, 2016.","DOI":"10.1016\/j.cmi.2015.09.018"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Al-Fattani MA, Douglas LJ: Biofilm matrix of Candida albicans<\/i> and Candida tropicalis<\/i>: chemical composition and role in drug resistance. J Med Microbiol 55: 999–1008, 2006.","DOI":"10.1099\/jmm.0.46569-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Zarnowski R, Westler WM, Lacmbouh GA, Marita JM, Bothe JR, Bernhardt J, et al: Novel entries in a fungal biofilm matrix encyclopedia. mBio 5: e01333-14, 2014.","DOI":"10.1128\/mBio.01333-14"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, et al: Putative role of \u03b2-1,3 glucans in Candida albicans<\/i> biofilm resistance. Antimicrob Agents Chemother 51: 510–20, 2007.","DOI":"10.1128\/AAC.01056-06"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nett JE, Crawford K, Marchillo K, Andes DR: Role of Fks1p and matrix glucan in Candida albicans<\/i> biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 54: 3505-8, 2010.","DOI":"10.1128\/AAC.00227-10"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lin JN, Lai CH, Chen YH, Chang LL, Lu PL, Tsai SS, et al: Characteristics and outcomes of polymicrobial bloodstream infections in the emergency department: a matched case-control study. Acad Emerg Med 17: 1072–9, 2010.","DOI":"10.1111\/j.1553-2712.2010.00871.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yo CH, Hsein YC, Wu YL, Hsu WT, Ma MHM, Tsai CH, et al: Clinical predictors and outcome impact of community-onset polymicrobial bloodstream infection. Int J Antimicrob Agents 54: 716–22, 2019.","DOI":"10.1016\/j.ijantimicag.2019.09.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Fukushima S, Hagiya H, Fujita K, Kamiyama S, Yamada H, Kishida M, et al: Clinical and microbiological characteristics of polymicrobial bacteremia: a retrospective, multicenter study. Infection 50: 1233–42, 2022.","DOI":"10.1007\/s15010-022-01799-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sancho S, Artero A, Zaragoza R, Camarena JJ, Gonz\u00e1lez R, Nogueira JM: Impact of nosocomial polymicrobial bloodstream infections on the outcome in critically ill patients. Eur J Clin Microbiol Infect Dis 31: 1791–6, 2012.","DOI":"10.1007\/s10096-011-1503-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Downes KJ, Metlay JP, Bell LM, McGowan KL, Elliott MR, Shah SS: Polymicrobial bloodstream infections among children and adolescents with central venous catheters evaluated in ambulatory care. Clin Infect Dis 46: 387–94 2008.","DOI":"10.1086\/525265"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN: Polymicrobial bloodstream infections involving Candida<\/i> species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 59: 401–6 2007.","DOI":"10.1016\/j.diagmicrobio.2007.07.001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tsai MH, Chu SM, Hsu JF, Lien R, Huang HR, Chiang MC, et al: Polymicrobial bloodstream infection in neonates: microbiology, clinical characteristics, and risk factors. PLoS One 9: e83082, 2014.","DOI":"10.1371\/journal.pone.0083082"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Pammi M, Zhong D, Johnson Y, Revell P, Versalovic J: Polymicrobial bloodstream infections in the neonatal intensive care unit are associated with increased mortality: a case-control study. BMC Infect Dis 14: 390, 2014.","DOI":"10.1186\/1471-2334-14-390"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Royo-Cebrecos C, Gudiol C, Ardanuy C, Pomares H, Calvo M, Carratal\u00e0 J: A fresh look at polymicrobial bloodstream infection in cancer patients. PLoS One 12: e0185768, 2017.","DOI":"10.1371\/journal.pone.0185768"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Liu Q, Liu X, Hu B, Xu H, Sun R, Li P, et al: Diagnostic performance and clinical impact of blood metagenomic next-generation sequencing in ICU patients suspected monomicrobial and polymicrobial bloodstream infections. Front Cell Infect Microbiol 13: 1192931, 2023.","DOI":"10.3389\/fcimb.2023.1192931"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Bouza E, Burillo A, Mu\u00f1oz P, Guinea J, Mar\u00edn M, Rodr\u00edguez-Cr\u00e9ixems M: Mixed bloodstream infections involving bacteria and Candida<\/i> spp. J Antimicrob Chemother 68: 1881–8, 2013.","DOI":"10.1093\/jac\/dkt099"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Rodr\u00edguez-Cr\u00e9ixems M, Mu\u00f1oz P, Mart\u00edn-Rabad\u00e1n P, Cercenado E, Guembe M, Bouza E: Evolution and aetiological shift of catheter-related bloodstream infection in a whole institution: the microbiology department may act as a watchtower. Clin Microbiol Infect 19: 845–51, 2013.","DOI":"10.1111\/1469-0691.12050"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Harriott MM, Noverr MC: Candida albicans<\/i> and Staphylococcus aureus<\/i> form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob Agents Chemother 53: 3914–22, 2009.","DOI":"10.1128\/AAC.00657-09"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kean R, Rajendran R, Haggarty J, Townsend EM, Short B, Burgess KE, et al: Candida albicans<\/i> mycofilms support Staphylococcus aureus<\/i> colonization and enhances miconazole resistance in dual-species interactions. Front Microbiol 8: 258, 2017.","DOI":"10.3389\/fmicb.2017.00258"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Short B, Delaney C, McKloud E, Brown JL, Kean R, Litherland GJ, et al: Investigating the transcriptome of Candida albicans<\/i> in a dual-species Staphylococcus aureus<\/i> biofilm model. Front Cell Infect Microbiol 11: 791523, 2021.","DOI":"10.3389\/fcimb.2021.791523"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Peters BM, Ovchinnikova ES, Krom BP, Schlecht LM, Zhou H, Hoyer LL, et al: Staphylococcus aureus<\/i> adherence to Candida albicans<\/i> hyphae is mediated by the hyphal adhesin Als3p. Microbiology 158: 2975–86, 2012.","DOI":"10.1099\/mic.0.062109-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kong EF, Tsui C, Kuchar\u00edkov\u00e1 S, Andes D, Van Dijck P, Jabra-Rizk MA: Commensal protection of Staphylococcus aureus<\/i> against antimicrobials by Candida albicans<\/i> biofilm matrix. mBio 7: e01365-16, 2016.","DOI":"10.1128\/mBio.01365-16"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Kong EF, Tsui C, Kuchar\u00edkov\u00e1 S, Van Dijck P, Jabra-Rizk MA: Modulation of Staphylococcus aureus<\/i> response to antimicrobials by the Candida albicans<\/i> quorum sensing molecule farnesol. Antimicrob Agents Chemother 61: e01573-17, 2017.","DOI":"10.1128\/AAC.01573-17"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME: Effect of farnesol on Staphylococcus aureus<\/i> biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 50: 1463–9, 2006.","DOI":"10.1128\/AAC.50.4.1463-1469.2006"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Inoue Y, Togashi N, Hamashima H: Farnesol-induced disruption of the Staphylococcus aureus<\/i> cytoplasmic membrane. Biol Pharm Bull 39: 653–6, 2016.","DOI":"10.1248\/bpb.b15-00416"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kaneko M, Togashi N, Hamashima H, Hirohara M, Inoue Y: Effect of farnesol on mevalonate pathway of Staphylococcus aureus<\/i>. J Antibiot 64: 547–9, 2011.","DOI":"10.1038\/ja.2011.49"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Boone CHT, Gutzmann DJ, Kramer JJ, Atkin AL, Nickerson KW: Quantitative assay for farnesol and the aromatic fusel alcohols from the fungus Candida albicans<\/i>. Appl Microbiol Biotechnol 106: 6759–73, 2022.","DOI":"10.1007\/s00253-022-12165-w"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) \tFehrmann C, Jurk K, Bertling A, Seidel G, Fegeler W, Kehrel BE, et al: Role for the fibrinogen-binding proteins coagulase and Efb in the Staphylococcus aureus<\/i>-Candida<\/i> interaction. Int J Med Microbiol 303: 230–8, 2013.","DOI":"10.1016\/j.ijmm.2013.02.011"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) \tMarcos M, Soriano A, I\u00f1urrieta A, Mart\u00ednez JA, Romero A, Cobos N, et al: Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J Antimicrob Chemother 66: 2119–25, 2011.","DOI":"10.1093\/jac\/dkr231"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Chaftari AM, Hachem R, Jiang Y, Shah P, Hussain A, Hamal Z A, et al: Changing epidemiology of catheter-related bloodstream infections in cancer patients. Infect Control Hosp Epidemiol 39: 727–9, 2018.","DOI":"10.1017\/ice.2018.75"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Lendak D, Puerta-Alcalde P, Moreno-Garc\u00eda E, Chumbita M, Garc\u00eda-Pouton N, Cardozo C, et al: Changing epidemiology of catheter-related bloodstream infections in neutropenic oncohematological patients. PLoS One 16: e0251010, 2021.","DOI":"10.1371\/journal.pone.0251010"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Braun E, Hussein K, Geffen Y, Rabino G, Bar-Lavie Y, Paul M: Predominance of Gram-negative bacilli among patients with catheter-related bloodstream infections. Clin Microbiol Infect 20: O627-9, 2014.","DOI":"10.1111\/1469-0691.12565"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Mandolfo S, Anesi A, Rognoni V: The epidemiology of central venous catheter-related bloodstream infection in our renal units is changing. J Vasc Access 23: 328–9, 2022.","DOI":"10.1177\/1129729821990222"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Kerr JR: Suppression of fungal growth exhibited by Pseudomonas aeruginosa<\/i>. J Clin Microbiol 32: 525–7, 1994.","DOI":"10.1128\/jcm.32.2.525-527.1994"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Kaleli I, Cevahir N, Demir M, Yildirim U, Sahin R: Anticandidal activity of Pseudomonas aeruginosa<\/i> strains isolated from clinical specimens. Mycoses 50: 74–8, 2007.","DOI":"10.1111\/j.1439-0507.2006.01322.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Hogan DA, Kolter R: Pseudomonas<\/i> - Candida<\/i> interactions: an ecological role for virulence factors. Science 296: 2229–32, 2002.","DOI":"10.1126\/science.1070784"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Bandara HM, Yau JY, Watt RM, Jin LJ, Samaranayake LP: Pseudomonas aeruginosa<\/i> inhibits in-vitro Candida<\/i> biofilm development. BMC Microbiol 10: 125, 2010.","DOI":"10.1186\/1471-2180-10-125"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Kerr JR, Taylor GW, Rutman A, H\u00f8iby N, Cole PJ, Wilson R: Pseudomonas aeruginosa<\/i> pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol 52: 385–7, 1999.","DOI":"10.1136\/jcp.52.5.385"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) McAlester G, O\u2019Gara F, Morrissey JP: Signal-mediated interactions between Pseudomonas aeruginosa<\/i> and Candida albicans<\/i>. J Med Microbiol 57: 563–9, 2008.","DOI":"10.1099\/jmm.0.47705-0"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Bandara HMHN, K Cheung BP, Watt RM, Jin LJ, Samaranayake LP: Pseudomonas aeruginosa<\/i> lipopolysaccharide inhibits Candida albicans<\/i> hyphae formation and alters gene expression during biofilm development. Mol Oral Microbiol 28: 54–69, 2013.","DOI":"10.1111\/omi.12006"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Fourie R, Cason ED, Albertyn J, Pohl CH: Transcriptional response of Candida albicans<\/i> to Pseudomonas aeruginosa<\/i> in a polymicrobial biofilm. G3 (Bethesda) 11: jkab042, 2021.","DOI":"10.1093\/g3journal\/jkab042"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Lopez-Medina E, Fan D, Coughlin LA, Ho EX, Lamont IL, Reimmann C, et al: Candida albicans<\/i> inhibits Pseudomonas aeruginosa<\/i> virulence through suppression of pyochelin and pyoverdine biosynthesis. PLoS Pathog 11: e1005129, 2015.","DOI":"10.1371\/journal.ppat.1005129"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Alam F, Catlow D, Di Maio A, Blair JMA, Hall RA: Candida albicans<\/i> enhances meropenem tolerance of Pseudomonas aeruginosa<\/i> in a dual-species biofilm. J Antimicrob Chemother 75: 925–35, 2020.","DOI":"10.1093\/jac\/dkz514"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Alam F, Blair JMA, Hall RA: Transcriptional profiling of Pseudomonas aeruginosa<\/i> mature single- and dual-species biofilms in response to meropenem. Microbiology (Reading) 169: 001271, 2023.","DOI":"10.1099\/mic.0.001271"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Zhao X, Jin Y, Bai F, Cheng Z, Wu W, Pan X: Mutation of PA4292<\/i> in Pseudomonas aeruginosa<\/i> increases \u03b2-lactam resistance through upregulating pyocyanin production. Antimicrob Agents Chemother 66: e0042122, 2022.","DOI":"10.1128\/aac.00421-22"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Schiessl KT, Hu F, Jo J, Nazia SZ, Wang B, Price-Whelan A, et al: Phenazine production promotes antibiotic tolerance and metabolic heterogeneity in Pseudomonas aeruginosa<\/i> biofilms. Nat Commun 10: 762, 2019.","DOI":"10.1038\/s41467-019-08733-w"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Hassuna NA, Darwish MK, Sayed M, Ibrahem RA: Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa<\/i>. Infect Drug Resist 13: 285–93, 2020.","DOI":"10.2147\/IDR.S233808"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Mashburn LM, Whiteley M: Membrane vesicles traffic signals and facilitate group activities in a prokaryote. Nature 437: 422–5, 2005.","DOI":"10.1038\/nature03925"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Alam F, Blackburn SA, Davis J, Massar K, Correia J, Tsai HJ, et al: Pseudomonas aeruginosa<\/i> increases the susceptibility of Candida albicans<\/i> to amphotericin B in dual-species biofilms. J Antimicrob Chemother 78: 2228–41, 2023.","DOI":"10.1093\/jac\/dkad228"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Eshima S, Kurakado S, Matsumoto Y, Kudo T, Sugita T: Candida\u00a0albicans<\/i> promotes the antimicrobial tolerance of Escherichia coli<\/i> in a cross-kingdom dual-species biofilm. Microorganisms 10: 2179, 2022.","DOI":"10.3390\/microorganisms10112179"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Bandara HMHN, Yau JYY, Watt RM, Jin LJ, Samaranayake LP: Escherichia coli<\/i> and its lipopolysaccharide modulate in vitro Candida<\/i> biofilm formation. J Med Microbiol 58: 1623–31, 2009.","DOI":"10.1099\/jmm.0.012989-0"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) De Brucker K, Tan Y, Vints K, De Cremer K, Braem A, Verstraeten N, et al: Fungal \u03b2-1,3-glucan increases ofloxacin tolerance of Escherichia coli<\/i> in a polymicrobial E. coli\/Candida albicans<\/i> biofilm. Antimicrob Agents Chemother 59: 3052–8, 2015.","DOI":"10.1128\/AAC.04650-14"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Bandara HM, Cheung BPK, Watt RM, Jin LJ, Samaranayake LP: Secretory products of Escherichia coli<\/i> biofilm modulate Candida<\/i> biofilm formation and hyphal development. J Investig Clin Dent 4: 186–99, 2013.","DOI":"10.1111\/jicd.12048"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Cabral DJ, Penumutchu S, Norris C, Morones-Ramirez JR, Belenky P: Microbial competition between Escherichia coli<\/i> and Candida albicans<\/i> reveals a soluble fungicidal factor. Microbial Cell 5: 249–55, 2018.","DOI":"10.15698\/mic2018.05.631"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Farrokhi Y, Al-shibli B, Al-hameedawi DFJ, Neshati Z, Makhdoumi A: Escherichia coli<\/i> enhances the virulence factors of Candida albicans<\/i>, the cause of vulvovaginal candidiasis, in a dual bacterial\/fungal biofilm. Res Microbiol 172: 103849, 2021.","DOI":"10.1016\/j.resmic.2021.103849"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Vila T, Kong EF, Montelongo-Jauregui D, Van Dijck P, Shetty AC, McCracken C, et al: Therapeutic implications of C. albicans<\/i>-S. aureus<\/i> mixed biofilm in a murine subcutaneous catheter model of polymicrobial infection. Virulence 12: 835–51, 2021.","DOI":"10.1080\/21505594.2021.1894834"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Capote-Bonato F, Bonato DV, Ayer IM, Magalh\u00e3es LF, Magalh\u00e3es GM, Pereira da C\u00e2mara Barros FF, et al: Murine model for the evaluation of candiduria caused by Candida tropicalis<\/i> from biofilm. Microb Pathog 117: 170–4, 2018.","DOI":"10.1016\/j.micpath.2018.02.036"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Yamamoto K, Tsujimura Y, Ato M: Catheter-associated Mycobacterium intracellulare<\/i> biofilm infection in C3HeB\/FeJ mice. Sci Rep 13: 17148, 2023.","DOI":"10.1038\/s41598-023-44403-0"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Alves-Barroco C, Botelho AMN, Am\u00e9rico MA, Fracalanzza SEL, de Matos APA, Guimaraes MA, et al: Assessing in vivo<\/i> and in vitro<\/i> biofilm development by Streptococcus dysgalactiae<\/i> subsp. dysgalactiae<\/i> using a murine model of catheter-associated biofilm and human keratinocyte cell. Front Cell Infect Microbiol 12: 874694, 2022.","DOI":"10.3389\/fcimb.2022.874694"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Matsumoto Y, Kurakado S, Sugita T: Evaluating Candida albicans<\/i> biofilm formation in silkworms. Med Mycol 59: 201–5, 2021.","DOI":"10.1093\/mmy\/myaa064"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Eshima S, Matsumoto Y, Kurakado S, Sugita T: Silkworm model of biofilm formation: In vivo<\/i> evaluation of antimicrobial tolerance of a cross-kingdom dual-species (Escherichia coli<\/i> and Candida albicans<\/i>) biofilm on catheter material. PLoS One 18: e0288452, 2023.","DOI":"10.1371\/journal.pone.0288452"}],"container-title":["Medical Mycology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/65\/3\/65_49\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T04:51:24Z","timestamp":1725079884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/65\/3\/65_49\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.24.004","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}